Limiting Patent Disputes: More Affordable Drugs and Biologics
New rules aim to facilitate the market entry of cheaper generic drugs and biosimilars. They limit the number of patents pharmaceutical companies can use in lawsuits, potentially speeding up access to medicines and lowering their prices for citizens. These changes apply to applications submitted after the law's enactment.
Key points
Pharmaceutical companies can only assert one patent per group in infringement lawsuits concerning generic drugs and biosimilars.
The goal is to reduce lengthy legal disputes that delay access to more affordable drug alternatives.
Citizens may gain faster access to cheaper versions of drugs and biologics, potentially lowering healthcare costs.
Introduced
Citizen Poll